Cautionary announcement – Discussions to conclude COVID-19 Licensing Agreement
ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen” or “the Company”)
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries (collectively “Aspen” or “the Group”)
CAUTIONARY ANNOUNCEMENT – DISCUSSIONS TO CONCLUDE COVID-19 LICENSING AGREEMENT
Shareholders are advised that Aspen are in advanced discussions in relation to the possible conclusion of a
licensing agreement to allow it to produce and sell a Covid-19 vaccine in Africa. Aspen currently produces
vaccines under contract on a ‘fill and finish’ basis.
The successful conclusion of this licensing agreement may have a material effect on the price of Aspen's
securities and, accordingly, shareholders are advised to exercise caution when dealing in the Company’s
securities.
Durban
29 November 2021
Sponsor
Investec Bank Limited
Date: 29-11-2021 05:20:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information.
